Sens. Baucus, Grassley Head Down Diverging Paths On Drug Price Negotiation As House Clears Pricing Measure
This article was originally published in The Pink Sheet Daily
Executive Summary
Baucus now favors repealing the noninterference clause but proceeding “cautiously.” Spotlight shifts to the Senate after the House clears HR 4.
You may also be interested in...
New Senator Udall Favors Lower Drug Prices, But Not Through Importation
Mark Udall, D-Colo., moves to the Senate with a health care record in the House that includes a "no" vote in 2003 on the Medicare Part D prescription benefit program
New Senator Udall Favors Lower Drug Prices, But Not Through Importation
Mark Udall, D-Colo., moves to the Senate with a health care record in the House that includes a "no" vote in 2003 on the Medicare Part D prescription benefit program
Part D Direct Negotiations Top AARP’s 2007 Advocacy Agenda
In addition to supporting lifting the ban on HHS directly negotiating prices with drug makers, AARP will push for legislation on drug importation and a pathway for generic biologics.